The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors

Current Medicinal Chemistry

Volumn 17, Issue 36, 2010, Pages 4551-4558

  Baskin, R ^a   Majumder, A ^a   Sayeski, P P ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

JAK2; Medicinal chemistry; Small molecule inhibitors; Structure activity relationships

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; 4 AMINOPYRAZOLO[3,4 D]PYRIMIDINE; 5 BROMOAMINOINDAZOLE; AMINO ACID; ASPARAGINE; AZ 960; BENZIMIDAZOLE; BENZOXAZOLE DERIVATIVE; CYT 387; GLYCINE; INTERLEUKIN 3; INTERLEUKIN 7; JANUS KINASE 2 INHIBITOR; LEUCINE; LS 104; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PYRAZINE; PYRAZOL 3 YL AMINE; PYRIMIDINE; QUINOXALINE; STAT3 PROTEIN; UNCLASSIFIED DRUG; WP 1066;

ARTICLE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; GLIOMA CELL; HYDROGEN BOND; IC 50; IN VITRO STUDY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; JANUS KINASE 2; MOLECULAR WEIGHT; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78650664262     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710794182953     Document Type: Article

References (40)

1. Witthuhn, B. A.; Quelle, F. W.; Silvennoinen, O.; Yi, T.; Tang, B.; Miura, O.; Ihle, J. N. JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell, 1993, 74(2), 227-36.
2. Argetsinger, L. S.; Campbell, G. S.; Yang, X. N.; Witthuhn, B. A.; Silvennoinen, O.; Ihle, J. N.; Cartersu, C. Identification of Jak2 as a Growth-Hormone Receptor-Associated Tyrosine Kinase. Cell, 1993, 74(2), 237-244.
3. Sattler, M.; Durstin, M. A.; Frank, D. A.; Okuda, K.; Kaushansky, K.; Salgia, R.; Griffin, J. D. The thrombopoietin receptor c-MPL activates JAK2 and TYK2 tyrosine kinases. Exp. Hematol., 1995, 23(9), 1040-8.
4. Peeters, P.; Raynaud, S. D.; Cools, J.; Wlodarska, I.; Grosgeorge, J.; Philip, P.; Monpoux, F.; Van Rompaey, L.; Baens, M.; Van den Berghe, H.; Marynen, P. Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t (9;12) in a lymphoid and t (9;15;12) in a myeloid leukemia. Blood, 1997, 90(7), 2535-40.
5. Joos, S.; Granzow, M.; Holtgreve-Grez, H.; Siebert, R.; Harder, L.; Martin-Subero, J. I.; Wolf, J.; Adamowicz, M.; Barth, T. F.; Lichter, P.; Jauch, A. Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2. Int. J. Cancer, 2003, 103(4), 489-95.
6. Reiter, A.; Walz, C.; Watmore, A.; Schoch, C.; Blau, I.; Schlegelberger, B.; Berger, U.; Telford, N.; Aruliah, S.; Yin, J. A.; Vanstraelen, D.; Barker, H. F.; Taylor, P. C.; O'Driscoll, A.; Benedetti, F.; Rudolph, C.; Kolb, H. J.; Hochhaus, A.; Hehlmann, R.; Chase, A.; Cross, N. C. The t (8;9) (p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCM1 to JAK2. Cancer Res., 2005, 65(7), 2662-7.
7. Griesinger, F.; Hennig, H.; Hillmer, F.; Podleschny, M.; Steffens, R.; Pies, A.; Wormann, B.; Haase, D.; Bohlander, S. K. A BCR-JAK2 fusion gene as the result of a t (9;22) (p24;q11.2) translocation in a patient with a clinically typical chronic myeloid leukemia. Genes Chromosomes Cancer, 2005, 44(3), 329-33.
8. Levine, R. L.; Wadleigh, M.; Cools, J.; Ebert, B. L.; Wernig, G.; Huntly, B. J.; Boggon, T. J.; Wlodarska, I.; Clark, J. J.; Moore, S.; Adelsperger, J.; Koo, S.; Lee, J. C.; Gabriel, S.; Mercher, T.; D'Andrea, A.; Frohling, S.; Dohner, K.; Marynen, P.; Vandenberghe, P.; Mesa, R. A.; Tefferi, A.; Griffin, J. D.; Eck, M. J.; Sellers, W. R.; Meyerson, M.; Golub, T. R.; Lee, S. J.; Gilliland, D. G. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005, 7(4), 387-97.
9. Kralovics, R.; Passamonti, F.; Buser, A. S.; Teo, S. S.; Tiedt, R.; Passweg, J. R.; Tichelli, A.; Cazzola, M.; Skoda, R. C. A gain-offunction mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med., 2005, 352(17), 1779-90.
10. James, C.; Ugo, V.; Le Couedic, J. P.; Staerk, J.; Delhommeau, F.; Lacout, C.; Garcon, L.; Raslova, H.; Berger, R.; Bennaceur-Griscelli, A.; Villeval, J. L.; Constantinescu, S. N.; Casadevall, N.; Vainchenker, W. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434(7037), 1144-8.
11. Baxter, E. J.; Scott, L. M.; Campbell, P. J.; East, C.; Fourouclas, N.; Swanton, S.; Vassiliou, G. S.; Bench, A. J.; Boyd, E. M.; Curtin, N.; Scott, M. A.; Erber, W. N.; Green, A. R. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet, 2005, 365(9464), 1054-61.
12. Zhao, R.; Xing, S.; Li, Z.; Fu, X.; Li, Q.; Krantz, S. B.; Zhao, Z. J. Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem., 2005, 280(24), 22788-92.
13. Schneider, H.; Cohen-Dayag, A.; Pecht, I. Tyrosine phosphorylation of phospholipase C gamma 1 couples the Fc epsilon receptor mediated signal to mast cells secretion. Int. Immunol., 1992, 4(4), 447-53.
14. Meydan, N.; Grunberger, T.; Dadi, H.; Shahar, M.; Arpaia, E.; Lapidot, Z.; Leeder, J. S.; Freedman, M.; Cohen, A.; Gazit, A.; Levitzki, A.; Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature, 1996, 379(6566), 645-8.
15. Gu, L.; Zhuang, H.; Safina, B.; Xiao, X. Y.; Bradford, W. W.; Rich, B. E. Combinatorial approach to identification of tyrphostin inhibitors of cytokine signaling. Bioorg. Med. Chem., 2005, 13(13), 4269-78.
16. Iwamaru, A.; Szymanski, S.; Iwado, E.; Aoki, H.; Yokoyama, T.; Fokt, I.; Hess, K.; Conrad, C.; Madden, T.; Sawaya, R.; Kondo, S.; Priebe, W.; Kondo, Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene, 2007, 26(17), 2435-44.
17. Ferrajoli, A.; Faderl, S.; Van, Q.; Koch, P.; Harris, D.; Liu, Z.; Hazan-Halevy, I.; Wang, Y.; Kantarjian, H. M.; Priebe, W.; Estrov, Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res., 2007, 67(23), 11291-9.
18. Lipka, D. B.; Hoffmann, L. S.; Heidel, F.; Markova, B.; Blum, M. C.; Breitenbuecher, F.; Kasper, S.; Kindler, T.; Levine, R. L.; Huber, C.; Fischer, T. LS104, a non-ATP-competitive smallmolecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells. Mol. Cancer Ther., 2008, 7(5), 1176-84.
19. Grunberger, T.; Demin, P.; Rounova, O.; Sharfe, N.; Cimpean, L.; Dadi, H.; Freywald, A.; Estrov, Z.; Roifman, C. M. Inhibition of acute lymphoblastic and myeloid leukemias by a novel kinase inhibitor. Blood, 2003, 102(12), 4153-8.
20. Tondel, K.; Anderssen, E.; Drablos, F. Protein Alpha Shape Similarity Analysis (PASSA): a new method for mapping protein binding sites. Application in the design of a selective inhibitor of tyrosine kinase 2. J. Comput. Aided Mol. Des., 2002, 16(11), 831-40.
21. Ledeboer, M. W.; Pierce, A. C.; Duffy, J. P.; Gao, H.; Messersmith, D.; Salituro, F. G.; Nanthakumar, S.; Come, J.; Zuccola, H. J.; Swenson, L.; Shlyakter, D.; Mahajan, S.; Hoock, T.; Fan, B.; Tsai, W. J.; Kolaczkowski, E.; Carrier, S.; Hogan, J. K.; Zessis, R.; Pazhanisamy, S.; Bennani, Y. L. 2-Aminopyrazolo [1, 5-a]pyrimidines as potent and selective inhibitors of JAK2. Bioorg. Med. Chem. Lett., 2009, 19(23), 6529-33.
22. Lucet, I. S.; Fantino, E.; Styles, M.; Bamert, R.; Patel, O.; Broughton, S. E.; Walter, M.; Burns, C. J.; Treutlein, H.; Wilks, A. F.; Rossjohn, J. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood, 2006, 107(1), 176-83.
23. Burns, C. J.; Bourke, D. G.; Andrau, L.; Bu, X.; Charman, S. A.; Donohue, A. C.; Fantino, E.; Farrugia, M.; Feutrill, J. T.; Joffe, M.; Kling, M. R.; Kurek, M.; Nero, T. L.; Nguyen, T.; Palmer, J. T.; Phillips, I.; Shackleford, D. M.; Sikanyika, H.; Styles, M.; Su, S.; Treutlein, H.; Zeng, J.; Wilks, A. F. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg. Med. Chem. Lett., 2009, 19(20), 5887-92.
24. Pardanani, A.; Lasho, T.; Smith, G.; Burns, C. J.; Fantino, E.; Tefferi, A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia, 2009, 23(8), 1441-5.
25. Wang, T.; Duffy, J. P.; Wang, J.; Halas, S.; Salituro, F. G.; Pierce, A. C.; Zuccola, H. J.; Black, J. R.; Hogan, J. K.; Jepson, S.; Shlyakter, D.; Mahajan, S.; Gu, Y.; Hoock, T.; Wood, M.; Furey, B. F.; Frantz, J. D.; Dauffenbach, L. M.; Germann, U. A.; Fan, B.; Namchuk, M.; Bennani, Y. L.; Ledeboer, M. W. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J. Med. Chem., 2009, 52(24), 7938-41.
26. Wang, T.; Ledeboer, M. W.; Duffy, J. P.; Pierce, A. C.; Zuccola, H. J.; Block, E.; Shlyakter, D.; Hogan, J. K.; Bennani, Y. L. A novel chemotype of kinase inhibitors: Discovery of 3, 4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(1), 153-6.
27. Gozgit, J. M.; Bebernitz, G.; Patil, P.; Ye, M.; Parmentier, J.; Wu, J.; Su, N.; Wang, T.; Ioannidis, S.; Davies, A.; Huszar, D.; Zinda, M. Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J. Biol. Chem., 2008, 283(47), 32334-43.
28. Ioannidis, S.; Lamb, M. L.; Davies, A. M.; Almeida, L.; Su, M.; Bebernitz, G.; Ye, M.; Bell, K.; Alimzhanov, M.; Zinda, M. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(23), 6524-8.
29. Ioannidis, S.; Lamb, M. L.; Almeida, L.; Guan, H.; Peng, B.; Bebernitz, G.; Bell, K.; Alimzhanov, M.; Zinda, M. Replacement of pyrazol-3-yl amine hinge binder with thiazol-2-yl amine: Discovery of potent and selective JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(5), 1669-73.
30. Antonysamy, S.; Hirst, G.; Park, F.; Sprengeler, P.; Stappenbeck, F.; Steensma, R.; Wilson, M.; Wong, M. Fragment-based discovery of JAK-2 inhibitors. Bioorg. Med. Chem. Lett., 2009, 19(1), 279-82.
31. Kiss, R.; Polgar, T.; Kirabo, A.; Sayyah, J.; Figueroa, N. C.; List, A. F.; Sokol, L.; Zuckerman, K. S.; Gali, M.; Bisht, K. S.; Sayeski, P. P.; Keseru, G. M. Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening. Bioorg. Med. Chem. Lett., 2009, 19(13), 3598-601.
32. Majumder, A.; Govindasamy, L.; Magis, A.; Kiss, R.; Polgar, T.; Baskin, R.; Allan, R. W.; Agbandje-McKenna, M.; Reuther, G. W.; Keseru, G. M.; Bisht, K. S.; Sayeski, P. P. Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core. J. Biol. Chem., 2010, 285(41), 31399-407.
33. Gerspacher, M.; Furet, P.; Pissot-Soldermann, C.; Gaul, C.; Holzer, P.; Vangrevelinghe, E.; Lang, M.; Erdmann, D.; Radimerski, T.; Regnier, C. H.; Chene, P.; De Pover, A.; Hofmann, F.; Baffert, F.; Buhl, T.; Aichholz, R.; Blasco, F.; Endres, R.; Trappe, J.; Drueckes, P. 2-Amino-aryl-7-aryl- benzoxazoles as potent, selective and orally available JAK2 inhibitors. Bioorg. Med. Chem. Lett., 2010, 20(5), 1724-7.
34. Furet, P.; Gerspacher, M.; Pissot-Soldermann, C. Design of two new chemotypes for inhibiting the Janus kinase 2 by scaffold morphing. Bioorg. Med. Chem. Lett., 2010, 20(6), 1858-60.
35. Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 443-70.
36. Bohm, H. J.; Banner, D.; Bendels, S.; Kansy, M.; Kuhn, B.; Muller, K.; Obst-Sander, U.; Stahl, M. Fluorine in medicinal chemistry. Chembiochem., 2004, 5(5), 637-43.
37. Van Heek, M.; France, C. F.; Compton, D. S.; McLeod, R. L.; Yumibe, N. P.; Alton, K. B.; Sybertz, E. J.; Davis, H. R., Jr. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J. Pharmacol. Exp. Ther., 1997, 283(1), 157-63.
38. Clader, J. W. The discovery of ezetimibe: a view from outside the receptor. J. Med. Chem., 2004, 47(1), 1-9.
39. Qiu, J.; Stevenson, S. H.; O'Beirne, M. J.; Silverman, R. B. 2, 6-Difluorophenol as a bioisostere of a carboxylic acid: bioisosteric analogues of gamma-aminobutyric acid. J. Med. Chem., 1999, 42(2), 329-32.
40. van Niel, M. B.; Beer, M. S.; Castro, J. L.; Cheng, S. K.; Evans, D. C.; Heald, A.; Hitzel, L.; Hunt, P.; Mortishire-Smith, R.; O'Connor, D.; Watt, A. P.; MacLeod, A. M. Parallel synthesis of 3-aryloxy-2-propanolamines and evaluation as dual affinity 5-HT (1A) and 5-HT re-uptake ligands. Bioorg. Med. Chem. Lett., 1999, 9(22), 3243-8.